STOCK TITAN

Avidity Biosciences Inc - RNA STOCK NEWS

Welcome to our dedicated news page for Avidity Biosciences (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Avidity Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avidity Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avidity Biosciences's position in the market.

Rhea-AI Summary
Avidity Biosciences announces positive data for AOC 1001 in treating myotonic dystrophy type 1 (DM1)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Avidity Biosciences will present at the 28th Annual Congress of the World Muscle Society, showcasing positive clinical trial data for AOC 1001 in Myotonic Dystrophy Type 1. The presentations will be available on Avidity's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
conferences
-
Rhea-AI Summary
Avidity Biosciences to participate in upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
conferences
Rhea-AI Summary
Avidity Biosciences grants non-qualified stock options and restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.33%
Tags
none
-
Rhea-AI Summary
Avidity Biosciences, Inc. is joining patient communities to raise awareness during National Muscular Dystrophy Awareness Month. The company is advancing clinical development programs for three types of muscular dystrophy with planned data readouts over the next 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Avidity Biosciences to present two poster presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
conferences
Rhea-AI Summary
Avidity Biosciences announces participation in upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
conferences
-
Rhea-AI Summary
Avidity Biosciences grants stock options and restricted stock units to new non-executive employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
none
-
Rhea-AI Summary
Avidity Biosciences has received Orphan Drug designation from the FDA for its investigational therapy, AOC 1044, for the treatment of Duchenne muscular dystrophy (DMD) in patients with exon 44 skipping mutations. AOC 1044 is being assessed in the EXPLORE44 clinical trial and is the first of multiple AOCs in development for DMD. Avidity plans to share results from the trial in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.7%
Tags
earnings
Avidity Biosciences Inc

Nasdaq:RNA

RNA Rankings

RNA Stock Data

2.03B
65.63M
6.41%
85.41%
10.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About RNA

avidity biosciences is pioneering a new class of precision medicines – antibody-sirna conjugates (asc™) – to deliver nucleic acid therapeutics against genetic drivers of disease. our ascs have drug-like properties similar to antibodies and antibody-drug conjugates. importantly, their unique sirna-based “payloads” permit selective targeting of disease-associated mrnas against virtually any target of interest. our leadership includes seasoned scientists and executives with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology. our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients. we strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. we have also attracted support from top-tier investors including f-prime capital, ecor1 capital, brace pharma and other sophisticated